At the heart of drug development for cardiovascular disease

Nathaniel Huebsch plans to grow heart muscle in the lab to predict drug response with a CAREER Award from the National Science Foundation

Shawn Ballard 
Confocal cross section of micro-engineered heart tissue (µEHT) derived from human induced pluripotent stem cells. Heart muscle cells (cardiomyocytes) are stained for sarcomere proteins alpha-actinin-2 (in red) and myosin binding protein-C (in green). The nuclei (in blue) provide insight into cell distribution, highlighting the interconnection of cells within the aligned tissue. (Image: Ghiska Ramahdita, Huebsch lab)
Confocal cross section of micro-engineered heart tissue (µEHT) derived from human induced pluripotent stem cells. Heart muscle cells (cardiomyocytes) are stained for sarcomere proteins alpha-actinin-2 (in red) and myosin binding protein-C (in green). The nuclei (in blue) provide insight into cell distribution, highlighting the interconnection of cells within the aligned tissue. (Image: Ghiska Ramahdita, Huebsch lab)

Heart disease, the leading cause of death in the United States, accounts for about 700,000 deaths annually, according to the Centers for Disease Control and Prevention. To help tackle this significant and wide-reaching health challenge, better drug treatments are needed. However, the lab-grown heart muscle used in drug development research does not accurately reflect how drugs will affect real patients, a major obstacle to developing drugs to treat cardiovascular disease.

With a five-year, $695,746 CAREER Award from the National Science Foundation, Nathaniel Huebsch, assistant professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, will grow heart muscle in the lab that is more representative of adult heart tissue and use that muscle to predict how drugs will affect patients’ hearts. CAREER awards support junior faculty who model the role of teacher-scholar through outstanding research, excellence in education and the integration of education and research within the context of the mission of their organization.

“Currently, heart muscle grown in the lab is more similar to heart muscle in a fetus than an adult,” Huebsch said. “We need to create lab-grown heart muscle that does a better job at predicting how real patients' heart muscle will respond to drugs. This is going to be especially useful for developing cures for genetically inherited diseases. It will also help us understand how to avoid cardiac side effects of drugs that are used to treat diseases like cancer, provide guidance on whether emerging therapies will work on certain diseases such as arrhythmias, and determine if there are more effective times for the application of therapies.”

Key to this endeavor is the integration of mechanical and metabolic cues during heart muscle development. Shortly after birth, babies’ hearts must pump with stronger force because their blood pressure increases. At the same time, their hearts’ energy source shifts from sugar to fat. Huebsch likens this shift to switching your car from regular to premium gas – you might not notice any difference unless you’re hauling a heavy load, or, in the case of a heart, pumping against greater resistance. By mimicking the dynamic changes in mechanical resistance that the heart muscle has to pump against, together with changes in energy source that occur during early postnatal life, Huebsch aims to enhance the maturity of lab-grown cardiac tissue.

“From our prior work, we know that the electrical behavior of heart muscle cells is exquisitely sensitive to mechanical forces, whether you’re looking at a real heart or lab-grown engineered heart tissue,” Huebsch said. “We now want to understand how the cells sense these mechanical forces and how they integrate the force sensing with the fuel source they use to produce the energy to pump against these forces.”

Huebsch’s CAREER award supports combining those factors and developing a deep, quantitative understanding of how different inputs affect heart behavior – a step he says will be critical to producing lab-grown muscle that accurately mimics real hearts.


The McKelvey School of Engineering at Washington University in St. Louis promotes independent inquiry and education with an emphasis on scientific excellence, innovation and collaboration without boundaries. McKelvey Engineering has top-ranked research and graduate programs across departments, particularly in biomedical engineering, environmental engineering and computing, and has one of the most selective undergraduate programs in the country. With 165 full-time faculty, 1,420 undergraduate students, 1,614 graduate students and 21,000 living alumni, we are working to solve some of society’s greatest challenges; to prepare students to become leaders and innovate throughout their careers; and to be a catalyst of economic development for the St. Louis region and beyond.

Click on the topics below for more stories in those areas

Back to News